Csenge Advisory Group purchased a new position in shares of Merck KGaA (OTCMKTS:MKGAF – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 14,011 shares of the company’s stock, valued at approximately $1,800,000.
A number of other institutional investors have also modified their holdings of MKGAF. Addison Advisors LLC purchased a new stake in shares of Merck KGaA in the 2nd quarter valued at $90,000. Comprehensive Financial Planning Inc. PA purchased a new position in Merck KGaA during the 2nd quarter valued at about $134,000. Stevens Capital Partners acquired a new position in Merck KGaA in the 2nd quarter valued at about $220,000. Kelman Lazarov Inc. acquired a new position in Merck KGaA in the 2nd quarter valued at about $448,000. Finally, BOK Financial Private Wealth Inc. acquired a new position in Merck KGaA in the 2nd quarter valued at about $523,000. 0.10% of the stock is owned by institutional investors and hedge funds.
Merck KGaA Stock Up 4.5%
Shares of OTCMKTS:MKGAF opened at $167.38 on Thursday. The firm has a market capitalization of $21.63 billion, a PE ratio of 25.55 and a beta of 0.96. Merck KGaA has a 1 year low of $116.68 and a 1 year high of $175.56. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.31 and a quick ratio of 0.84. The firm’s 50-day moving average is $162.50 and its two-hundred day moving average is $148.28.
Merck KGaA Profile
Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.
The company’s operations are organized mainly into three businesses.
Recommended Stories
- Five stocks we like better than Merck KGaA
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Want to see what other hedge funds are holding MKGAF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck KGaA (OTCMKTS:MKGAF – Free Report).
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
